A B S T R A C T Immunological detection of elastase, an enzyme present within leukocyte granules, has been used as a marker for polymorphonuclear leukocyte activation. Polymorphonuclear leukocytes contained 4.6 gg/107 cells, whereas erythrocytes, mononuclear cells, and platelets contained < 1% of this level. In plasma that was separated from blood cells after 1 h at 22°C, the mean level of elastase-related antigen in seven normal donors was 25±6 ng/ml. This level was unaltered by immediate separation of the plasma from the cells, by inclusion of protease inhibitors, or by anticoagulation of the plasma with either EDTA or acidcitrate-dextrose (the level in heparinized plasma was approximately threefold higher). In serum, the level of elastase-related antigen was 288±125 ng/ml, representing an 11.5-fold increase above plasma levels. The antigen detected in serum was immunochemically indistinguishable from the leukocyte enzyme. Release of elastase was observed when isolated polymorphonuclear leukocytes were added to nonanticoagulated platelet-rich or platelet-poor plasma, recalcified plasma, or to serum. Addition of a chelating agent to serum prevented elastase release, but calcium or magnesium did not induce release in the absence of plasma. Coagulation induced by addition of thrombin to plasma also failed to induce release. In whole blood or in anticoagulated plasma reconstituted with polymorphonuclear leukocytes and then recalcified, initial release of elastase occurred concomitantly with or slightly after clotting and reached maximal levels within 20-40 min after clot formation. The data indicates that early events in coagulation or other pathways that occur in parallel with coagulation induce leukocyte release. The release of elastase, a major fibrinolytic protease of leukocytes, from the cells provides a mechanism Portions of this study were presented at the
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The fibrinolytic activity of leukocyte extracts is independent of the plasminogen system as plasmin (ogen) inhibitors and activators fail to inhibit or augment fibrinolytic activity (4, 11) and fibrinogen degradation products generated by leukocyte proteases are structurally and immunochemically distinguishable from plasmin-derived degradation products (4, 12, 13) . A variety of neutral proteases (5, (14) (15) (16) (17) (18) and acidic cathepsins (3) of neutrophils are capable of degrading fibrin (ogen). Within leukocyte granules, elastase has been identified as one of the major fibrinolytic proteases active at neutral pH (19) . In this study, a specific radioimmunoassay for leukocyte elastase has been de-veloped, and the detection of this antigen has been used as a marker for leukocyte activation. The data demonstrate that this enzyme is released from the cell in association with blood coagulation.
METHODS
Cell isolation. Human leukocytes were isolated from citrated blood by differential sedimentation in 1% dextran followed by brief hypotonic or NH4Cl lysis of residual erythrocytes (4, 20) . The isolated cells consisted of 75-85% polymorphonuclear leukocytes (PMN)' and 10-20% mononuclear cells. Other cell types and purer preparations of PMN were isolated by placing 10-ml aliquots of heparinized blood onto 3 ml of Ficoll-Hypaque (density 1.074 g/cm3) and centrifuging at 2,260 g for 6 min at 20°C. Mononuclear cells were removed from the interface and washed three to five times in PBS. Erythrocytes and PMN were recovered from the pellets of the Ficoll-Hypaque gradient and separated by dextran sedimentation and NH4Cl lysis. The purity of the isolated cells determined by neutral red and Giemsa staining was as follows: the mononuclear cells contained 80-85% lymphocytes, 10-20% monocytes with <2% PMN; PMN contained <3% mononuclear cells, and .0.1% erythrocytes; the erythrocytes contained <0.05% PMN. Platelets were prepared by differential centrifugation followed by gel filtration (21) and contained .0.05% PMN. Isolation of leukocyte elastase. Leukocyte granules were isolated by differential ultracentrifugation (22) and disrupted by repeated freezing and thawing. The extracts were applied to a 2.5 X 40-cm column of CM-Sephadex C50 (Pharmacia Fine Chemicals, Piscataway, N. J.) equilibrated with 0.1 M NaCl, 0.05 M sodium phosphate, pH 7.2, and a linear gradient was developed with a final buffer of 1.0 M NaCl, 0.05 M sodium phosphate, pH 7.2. Fractions containing elastase activity, identified by hydrolysis of the N-tBOC-L-alanine-p-nitro-phenylester (23) were concentrated by ammonium sulfate precipitation at 80% saturation, and applied to a 1.5 X 20-cm column of elastin-Sepharose (20 mg elastin/ ml Sepharose) at 4°C (24) . After extensive washing with buffers containing 0.15 M and 1.0 M NaCl, the purified elastase was eluted with 8 Assays of PMN function. The leukocyte release reaction was induced with serum-activated zymosan particles (ICN Nutritional Biochemicals, Cleveland, Ohio) prepared as described (4). Leukocytes, 1 X 107 cells in 1 ml of Puck saline G, were added to 10 mg of serum-activated or control particles (prepared in an identical inanner without serum activation) and incubated for 30 min at 37°C with agitation. Cells and particles were removed by centrifugation at 800 g for 10 min, and elastase antigen was measured in the suppernatant. Percent release was calculated relative to the elastase solubilized by repeated freezing and thawing of leukocytes. Lactic dehydrogenase was used as a marker of cell lysis and was measured by the rate of NAD reduction (4, 27) .
For 51Cr labeling of leukocytes, PMN isolated by centrifugation through Ficoll-Hypaque gradients followed by dextran sedimentation were used. PMN (5 X 108 cells) were suspended in 1 ml PBS and 200 MCi 51Cr (New England Nuclear, Boston, Mass.) was added. After a 30-min incubation at 37°C, 9 ml PBS was added, and the cells were centrifuged through 3 ml Ficoll-Hypaque. This washing procedure was repeated once followed by three additional washes in 0.15 M NaCl, 0.01 M phosphate buffer, pH 7.3 (PBS).
Centrifugation-induced release was assessed by fixing the PMN with paraformaldehyde before centrifugation. Calcium was added to one of two identical aliquots of PMN (107/ml) in acid-citrate-dextrose (ACD) plasma, and after 1 h at 37°C, the clot was wrung and removed from the recalcified sample. Paraformaldehyde (4% in PBS) was added to both samples to a final 2% concentration; and after 1 h at 37°C, an equal volume of 0.2 M Tris, pH 7.2, was added. After 10 min, the cells were recovered by centrifugation and tested for their capacity to undergo release with zymosan particles.
Analytical procedures. Polyacrylamide gel electrophoresis was performed on 7.5% gels in the presence of sodium dodecylsulfate (SDS) under nonreducing conditions (28) . Double immunodiffusion analysis was performed in 1% agarose in PBS. Blood was drawn by venepuncture into plastic syringes or evacuated tubes containing 1.5 mg either K3EDTA, 15 USP U heparin or 0.14 ml ACD-solution per milliliter of blood. Removal of cells or clots was achieved by centrifugation at 1,200 g for 10 min at 22°C.
RESULTS
Elastase was isolated from leukocyte granules by ion exchange and affinity chromatography. The isolated enzyme yielded a single band on SDS polyacrylamide gels under nonreducing condition ( Fig. 1 of 5 ,iCi/,ug, >95% of the radioactivity migrated as a single peak on a SDS polyacrylamide gel with a mobility identical to that of the stained protein ( Fig.  1A and B). Antiserum to leukocyte elastase, raised in rabbits, formed a single precipitin line with isolated elastase and with the extract of leukocyte granules, and these precipitin lines fused in a reaction of complete antigenic identity (Fig. 1C) . For quantitation of leukocyte elastase, a competitive inhibition radioimmunoassay of the double antibody type was developed. As shown in Fig. 2 , nonlabeled elastase yielded a typical semilogarithmic inhibition profile producing complete competitive inhibition at 50 ng/ml and 50% relative inhibition at 3 ng/ml. Dur- ing the course of this study, the limit of sensitivity of the radioimmunoassay (10% relative inhibition) was 0.47±0.36 ng/ml. A soluble extract of leukocyte granules also produced complete competitive inhibition and yielded an inhibition slope similar to that of the isolated enzyme. This antigenic identity suggested minimal immunochemical alteration of the enzyme during isolation. Cathepsin G, purified from leukocyte granules, failed to produce inhibition at 1 gg/ml.
The specificity of leukocyte elastase as a marker for PMN and their activation was assessed with respect to: (a) restriction of elastase-related antigen to the PMN as contrasted to other cells, and (b) the capacity to detect secretion of elastase from stimulated leukocytes. Human peripheral blood cells were fractionated into PMN, platelet, erythrocyte, and mononuclear cell populations, and the elastase-related antigen in the detergent-solubilized extracts of the cells was quantitated by radioimmunoassay. As shown in Table I , the PMN extract contained at least 130-fold more elastase-related antigen than the other cell populations. Thus, the low levels of elastase-related antigen detected in other cell populations could be accounted for by less than a 1% PMN contamination. The level of 4.6 ,ug/107 PMN is within the range of -1-12 jg elastase/107 PMN reported by others (16, 29) .
The capacity to detect the nonlytic release of elastase-related antigen from PMN was assessed by using serum-activated zymosan particles to stimulate leukocyte secretion. Activated zymosan stimulated release of elastase-related antigen from the PMN thaw controls, 39.1±27.1% of the antigen was released by the activated zymosan as contrasted to a 7±5.1% release induced by the unactivated zymosan particles.
Although the zymosan-induced release of elastase was quite variable among the donors, each individual cell preparation exhibited at least a threefold increase above the corresponding sample treated with unactivated zymosan. As a control for cytolysis, lactic acid dehydrogenase activity was measured; and; with both activated and nonactivated zymosan, <4% of total cellular content was solubilized. These results indicate that elastase-related antigen is restricted to the PMN and that its secretion may be detected and quantitated. With these assurances of specificity and sensitivity, the levels of elastase-related antigen in serum and plasma of normal donors was assessed. Blood samples were drawn into ACD anticoagulant or no anticoagulant and incubated for 1 h at 22°C before removal of the blood clots and/or cells by centrifugation to obtain the serum and plasma samples. Elastase-related antigen was detected in all plasmas (seven donors) at the low level of 25±6 ng/ml. In contrast, a mean of 288±125 ng elastase/ml was detected in the sera, representing a mean increase of 11.5-fold over plasma levels. This increase was observed in all clotted samples and ranged from a 4.4-to a 20.0-fold increase. The competitive inhibition produced by serial dilutions of a serum and plasma sample from the same donor in the radioimmunoassay are included in Fig. 2 . At low dilution, the serum sample produced complete competitive inhibition and yielded an inhibition slope parallel to that of isolated leukocyte elastase. The plasma sample contained insufficient elastase-related antigen to produce complete inhibition but also yielded a slope parallel to the isolated enzyme. In separate experiments (not shown), it was demonstrated that addition of isolated leukocyte elastase or elastase inactivated with DFP to serum or plasma generated superimposable inhibition curves, indicating that the capacity to detect elastase-related antigen in enzymatically active or nonactive form was equivalent in plasma and serum.
The data indicated that low levels of elastase-related antigen were present in normal plasma and that when blood was permitted to clot, the level of elastase-related antigen in the resultant serum increased markedly. The basis for the elastase-related antigen in plasma was further investigated by examining the effects of anticoagulants and incubation time. Venous blood was drawn into ACD, EDTA, or heparin, as well as into the combination of these anticoagulants supplemented with the protease inhibitors, 6-aminohexanoic acid, aprotinin, and hirudin, and incubated 1 h at 22°C before separation of the plasma. In addition, blood drawn into the combination of anticoagulants and protease inhibitors was immediately centrifuged at 4°C (10 min required for plasma separation). The blood drawn into ACD, EDTA, or the combination of anticoagulants and inhibitors contained very similar levels of elastase-related antigen (Table II) . The quantity of elastase-related antigen in heparinized plasma was approximately threefold higher than in the other anticoagulants. Immediate separation of the blood drawn into the combination of anticoagulants and inhibitors did not diminish the plasma elastase level. Thus, normal plasma appeared to contain a basal level of leukocyte elastase-related antigen that could not be attributed to in vitro liberation of the enzyme from leukocytes.
The increase in serum elastase-related antigen was further characterized by experiments in which celldepleted plasma samples were reconstituted with PMN. Isolated PMN were added to ACD plasma, nonanticoagulated plasma (both platelet-rich and plateletpoor plasma), serum, or serum to which ACD was t These samples were drawn into plastic syringes containing ACD supplemented with 10 mM EDTA, 0.2 M 6-aminohexanoic acid, 100 U aprotinin/ml and 50 U hirudin/ml (final concentrations).
added. The elastase-related antigen within the resultant plasma or serum samples was determined after a 1-h incubation at 22°C. The data shown in Table III illustrates the following points: (a) PMN incubated in ACD plasma did not spontaneously liberate elastaserelated antigen; the elastase level within the ACD plasma incubated with cells was only 1.8-fold greater than in the plasma without added cells. (b) In the absence of anticoagulant, the level of elastase-related antigen in the resultant serum increased markedly, and this increase was independent of the presence or absence of platelets within the plasma. (c) A similar marked increase was observed when PMN were added to serum, indicating that the factors responsible for the liberation of elastase from PMN were maintained in serum. (d) Addition of ACD to serum prevented the release of elastase, suggesting a potential role for divalent ions in liberation of the enzyme.
The relationship between divalent ions, plasma, and the release of elastase was further examined. Isolated PMN were suspended in Puck's saline A, which lacks both calcium and magnesium. Calcium, magnesium, thrombin, plasma, or combinations of the agents were added to the cell suspensions, and elastase release was measured after 1 h at 22°C. As shown in Table IV , calcium, magnesium, or the combination of these divalent ions were in themselves not sufficient to induce elastase release. Similarly, thrombin alone or clotting induced by the combination of thrombin and plasma failed to liberate elastase-related antigen. Only when both plasma and calcium were added to the cells (which resulted in clot formation), was a significant increase of elastase in the soluble fraction observed.
Cell lysis or nonlytic secretion represent possible and death could be reasonably excluded as the basis for elastase release. The role of centrifugation in the induction of elastase release was evaluated. Two samples of PMN (107 cells/ml) were placed in ACD-plasma, and clotting was induced in one by recalcification. After 1 h at 37°C the clot was wrung and removed with a wooden applicator. Paraformaldehyde was added to a final concentration of 2% to both samples, and the cells were fixed for 1 h at 37°C. An equal volume of 0.2 M Tris, pH 7.2, was then added to neutralize excess paraformaldehyde, and the cells were then removed by centrifugation. The elastase-related antigen in recalcified and fixed samples was 390 ng/ml compared with 400 ng/ml in a sample treated in parallel but omitting the paraformaldehyde. In the nonclotted samples, these values were 32 and 28 ng/ml for the fixed and nonfixed samples, respectively. Fixation of the cells was verified by showing that the paraformaldehyde-treated cells failed to release elastase-related antigen when stimulated with activated zymosan particles. Thus, the release of elastase from the cells in association with clotting was not dependent upon centrifugation of the cells.
The rate of elastase secretion from PMN in clotting whole blood or in plasma was assessed. The results shown in Fig. 3A (Fig. 3B ). With addition of calcium, clotting occurred at 8 min, and an increase in serum elastase was noted at 15 min. This increase again reached maximal levels at 45 min. In the absence of calcium, a slight increase in elastase-related antigen was detected between 5 and 15 min but then showed no subsequent change.
The interaction of elastase released from the PMN with plasma proteins such as protease inhibitors was evaluated in gel filtration experiments. A Sephadex G100 column (1.5 X 90 cm) was calibrated with free '251-elastase (inactivated with DFP), with 125I-elastase added to serum before gel filtration, as well as from the elution pattern of serum proteins. As shown in Fig.  4A , free '25I-elastase eluted as a single peak beyond the elution position of albumin, consistent with its mol wt of 30,000. In contrast, when 1251-elastase was added to serum, no radioactivity was detected in the position of free elastase. Instead, a major peak of radioactivity eluted slightly before the albumin peak. The estimated mol wt of this peak at 80,000 is consistent with the formation of a 1:1 stoichiometric complex between elastase and its primary serum inhibitor, a1-antitrypsin (29) . In addition, a smaller proportion of the radioactivity eluted at the void volume of the column, perhaps arising from complex formation between elastase and a2-macroglobulin, a second serum inhibitor of the enzyme. In Fig. 4B , serum derived 60 min after recalcification of PMN-rich plasma was applied to the column and the elastase-related antigen in the eluate was quantitated by radioimmunoassay. Two peaks of antigen were detected, and their elution positions were identical to those obtained when active 1251-elastase was added to serum. No elastase-related antigen was detected in the position of the free enzyme.
DISCUSSION
In this study, the detection of elastase-related antigen has been used as a marker for PMN activation. Other cells, including platelets (30) and macrophages (31) , contain enzymes with elastolytic activity, but these enzymes appear to be immunologically unrelated to PMN elastase. The levels of elastase-related antigen detected in the extracts of other cell types could be accounted for by less than a 1% PM The sensitivity of the radioimmur -0.5 ng/ml of elastase-related antil mitted ready quantitation of the elast zymosan-stimulated PMN. In plasm of elastase-related antigen detected Anticoagulation of the plasma with citrate and EDTA, did not alter ti heparinized plasma contained three of elastase-related antigen. Immedi the cells from the plasma and add inhibitors failed to change the p1aw antigen. These results would sugge low levels of elastase-related antigen in vivo. Of greater significance wa that serum levels of elastase were m above plasma levels. With a1-Antitrypsin and a2-macroglobulin are known inhibitors of leukocyte elastase (29) and the formation of these enzyme inhibitor complexes reasonably explains the gel filtration patterns observed. The ultimate formation of such complexes does not, however, pre-clude a physiological role for the released enzyme. The interaction of elastase with elastin has been shown to protect the enzyme from a1-antitrypsin (36) . The binding of elastase to fibrin(ogen) or other potential substrates could also prolong its half-life.
Elastase is an enzyme of broad proteolytic specificity. In addition to fibrinogen, other coagulation factors (5), complement (37) , fibronectin (38) , plasminogen (39) , and immunoglobulins (40) have been shown to be substrates for elastase. Degradation by elastase of elastin within lungs has been implicated in the tissue damage associated with emphysema (41) , and high concentrations of the enzyme are also found within rheumatoid synovial tissue (42) . Furthermore, it is reasonable to assume that PMN release of elastase is not selective, so that other proteases within the leukocyte granules would also be secreted. Thus, leukocyte release associated with blood coagulation may have broad physiological and pathophysiological implications. 
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